-
Drug Design, Development and Therapy
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Silodosin in the treatment of benign prostatic hyperplasia
Review
(8131) Total Article Views
Authors: Maxime Rossi, Thierry Roumeguère
Published Date October 2010 Volume 2010:4 Pages 291 - 297
DOI: http://dx.doi.org/10.2147/DDDT.S10428
Maxime Rossi, Thierry RoumeguèreDepartment of Urology, Erasme Hospital, University Clinics of Brussels, ULB, Brussels, Belgium
Abstract: Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms and flow rate improvement, and this is clearly demonstrated in placebo-controlled trials with extensions out to five years. These agents have been shown to prevent symptomatic progression of the disease. The aim of this article is to offer a critical review of the current literature on silodosin, formerly known as KMD-3213, a novel alpha-blocker with unprecedented selectivity for a1A-adrenergic receptors, as compared with both a1B- and a1D -adrenoceptors, exceeding the selectivity of all currently used a1-blockers, and with clinically promising effects.
Keywords: silodosin, a1A- blockers, lower urinary tract symptoms, benign prostatic hyperplasia, uroselectivity
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- Testimonials
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
- The benefits and risks of testosterone replacement therapy: a review
- Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
- Tenofovir-associated bone density loss